• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Belite Bio Inc

    3/31/26 8:01:39 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BLTE alert in real time by email
    6-K 1 tm261133d2_6k.htm FORM 6-K

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15b-16 OF

    THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of March 2026

     

    Commission File Number: 001-41359

     

    Belite Bio, Inc

    (Exact name of registrant as specified in its charter)

     

    Not Applicable

    (Translation of Registrant´s name into English)

     

    12750 High Bluff Drive Suite 475,

    San Diego, CA 92130

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

     

    Form 20-F x Form 40-F ¨

     

     

     

     

     

     

    On March 31, 2026, Belite Bio, Inc issued a press release entitled “Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website”. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

     

    This Report on Form 6-K shall be deemed to be incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933, and shall be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

     

    EXHIBIT INDEX

     

    Exhibit 99.1 — Press Release

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      Belite Bio, Inc
         
      By: /s/ Yu-Hsin Lin
      Name: Yu-Hsin Lin
      Title: Chief Executive Officer and Chairman

     

    Date: March 31, 2026

     

     

     

    Get the next $BLTE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLTE

    DatePrice TargetRatingAnalyst
    1/26/2026$195.00Buy
    BofA Securities
    1/6/2026$191.00Overweight
    Morgan Stanley
    12/2/2025$194.00Neutral → Outperform
    Mizuho
    11/24/2025$154.00Overweight
    Cantor Fitzgerald
    11/20/2025$105.00Neutral
    Mizuho
    12/14/2023$60.00Buy
    Maxim Group
    7/28/2023$43.00Overweight
    Cantor Fitzgerald
    7/26/2023$25.00Outperform
    SVB Securities
    More analyst ratings

    $BLTE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities initiated coverage on Belite Bio with a new price target

    BofA Securities initiated coverage of Belite Bio with a rating of Buy and set a new price target of $195.00

    1/26/26 10:01:23 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on Belite Bio with a new price target

    Morgan Stanley initiated coverage of Belite Bio with a rating of Overweight and set a new price target of $191.00

    1/6/26 8:54:10 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Belite Bio upgraded by Mizuho with a new price target

    Mizuho upgraded Belite Bio from Neutral to Outperform and set a new price target of $194.00

    12/2/25 8:17:09 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

    SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio®" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 4:00 pm ET. Webcast Link InstructionsWebcasts of the presentations can be accessed under "Events" in the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events. The replays will be archived for 90 days f

    6/2/26 8:00:00 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update

    Initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant for the treatment of Stargardt disease type 1 (STGD1); submission expected to be completed in the second quarter of 2026Commercialization preparation for STGD1 underway; hiring of all key commercial leadership positions completed Cash and cash equivalents, U.S. treasury bills and notes: $798.6 million as of March 31, 2026Conference call and webcast on Wednesday, May 20, 2026, at 4:30 p.m. ET SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio®" or the "Company"), a clinical-stage drug development company focused on advancing nov

    5/20/26 6:00:00 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland

    Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease, having met the primary endpoint, reductions in lesion growth rate, in the pivotal, global Phase 3 DRAGON trial Company recently initiated a rolling submission of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA), which it expects to complete in 2Q 2026 Tinlarebant has previously been granted Breakthrough Therapy, Fast Track and Rare Pediatric Disease Designations in the U.S., Orphan Drug Designation in the U.S., Europe, and Japan, and Pioneer Drug Designation in Japan for the treatment of Stargardt disease SAN DIEGO, May 18, 2026 (GLOBE NEWSWIRE) -- Belite Bi

    5/18/26 4:00:00 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Mata Nathan L. sold $102,039 worth of American depositary share (666 units at $153.21) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)

    4 - BELITE BIO, INC (0001889109) (Issuer)

    5/8/26 4:45:44 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Scientific Officer Mata Nathan L. sold $153,839 worth of American depositary share (1,000 units at $153.84) as part of a pre-agreed trading plan, decreasing direct ownership by 60% to 666 units (SEC Form 4)

    4 - BELITE BIO, INC (0001889109) (Issuer)

    5/7/26 4:15:04 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Scientific Officer Mata Nathan L. sold $155,502 worth of American depositary share (1,000 units at $155.50) as part of a pre-agreed trading plan, decreasing direct ownership by 38% to 1,666 units (SEC Form 4)

    4 - BELITE BIO, INC (0001889109) (Issuer)

    5/6/26 4:15:08 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    SEC Filings

    View All

    SEC Form 6-K filed by Belite Bio Inc

    6-K - BELITE BIO, INC (0001889109) (Filer)

    5/20/26 6:02:06 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Belite Bio Inc

    6-K - BELITE BIO, INC (0001889109) (Filer)

    4/21/26 4:00:16 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Belite Bio Inc

    144 - BELITE BIO, INC (0001889109) (Subject)

    4/9/26 12:17:43 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    Leadership Updates

    Live Leadership Updates

    View All

    Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update

    Initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant for the treatment of Stargardt disease type 1 (STGD1); submission expected to be completed in the second quarter of 2026Commercialization preparation for STGD1 underway; hiring of all key commercial leadership positions completed Cash and cash equivalents, U.S. treasury bills and notes: $798.6 million as of March 31, 2026Conference call and webcast on Wednesday, May 20, 2026, at 4:30 p.m. ET SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio®" or the "Company"), a clinical-stage drug development company focused on advancing nov

    5/20/26 6:00:00 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer

    Dr. Scholl is a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest ever natural history study of Stargardt disease SAN DIEGO, Sept. 01, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio" or the "Company"), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its board of directors has appointed Hendrik P. N. Scholl, MD, MA, as the Chief Medical Officer of the Company, effective immediately. Dr. Scholl is the foremost globally recognized authority on Stargar

    9/1/24 8:00:00 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    Financials

    Live finance-specific insights

    View All

    New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease

    Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in a global Phase 3 trial for Stargardt disease, achieving a statistically significant p-value of 0.0033Tinlarebant met the primary efficacy endpoint, demonstrating clinical benefit by significantly reducing the lesion growth rate by 36% compared to placebo, as measured by retinal imagingTinlarebant was well tolerated throughout the trial Stargardt disease impacts more than 50,000 patients in the U.S. Belite Bio plans to file an NDA with the US FDA in 1H 2026Company will host a conference call and webcast today at 8:00 a.m. ET SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite

    12/1/25 6:00:00 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

    Dosed first patient in Phase 2/3 DRAGON II trial of Tinlarebant for the treatment of Stargardt disease (STGD1)Pivotal global Phase 3 PHOENIX trial of Tinlarebant in geographic atrophy (GA) subjects is ongoing with more than 280 subjects enrolledAppointed Hendrik P.N. Scholl, MD, MA, a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest natural history study of Stargardt disease, as Chief Medical OfficerInterim analysis from the pivotal global Phase 3 DRAGON trial of Tinlarebant in adolescent STGD1 subjects anticipated by end of 2024 or early 2025Company to host webcast on Tuesday, November 12, 2024, at 4:30 p.m. EST SAN DIEGO,

    11/12/24 1:00:25 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results

    Completed enrollment in pivotal Phase 3 "DRAGON" trial for Tinlarebant in adolescent Stargardt disease ("STGD1") with 104 subjects enrolled across 11 countries worldwideFirst subject dosed with Tinlarebant in pivotal global Phase 3 "PHOENIX" trial in Geographic Atrophy ("GA")Oral, once-daily Tinlarebant continues to be safe and well tolerated, slowing expansion of autofluorescence, reducing incident atrophic retinal lesion growth rate, and stabilizing visual acuity up to 24-months in Phase 2 STGD1 trial ("LBS-008-CT02")Interim Phase 3 safety and efficacy data from pivotal "DRAGON" trial expected in 2H 2024Conference Call and Webcast Tuesday, November 14, 2023, at 4:30 p.m. ET

    11/13/23 8:15:47 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Belite Bio Inc

    SC 13G - BELITE BIO, INC (0001889109) (Subject)

    2/12/24 9:08:25 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Belite Bio Inc

    SC 13G - BELITE BIO, INC (0001889109) (Subject)

    2/12/24 8:40:46 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Belite Bio Inc

    SC 13G - BELITE BIO, INC (0001889109) (Subject)

    2/15/23 1:36:20 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care